Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma - PubMed
2 hours ago
- #Metastatic Renal Cell Carcinoma
- #Immunotherapy
- #Clinical Trials
- The study compares efficacy, statistical robustness, and censoring patterns across four phase 3 RCTs of immune-based combinations (nivolumab + ipilimumab, nivolumab + cabozantinib, pembrolizumab + axitinib, pembrolizumab + lenvatinib) versus sunitinib in first-line metastatic renal cell carcinoma.
- 58-month restricted-mean survival time difference for overall survival ranged from 3.5 months (CLEAR/pembrolizumab + lenvatinib) to 5.1 months (CheckMate-9ER/nivolumab + cabozantinib), with all studies showing significant censoring in the control arm for progression-free survival.
- After adjusting for censoring, only the CLEAR trial lost statistical significance for overall survival benefit; nivolumab-based combinations and pembrolizumab + axitinib demonstrated more robust overall survival results compared to pembrolizumab + lenvatinib.